CRISPR Therapeutics recently reported that rollout of its approved gene therapy Casgevy for sickle cell disease and transfusion‑dependent beta thalassemia has been slower than hoped, contributing to a ...

Regulatory tailwinds and weak earnings set the stage The FDA's draft guidance to speed approval of genome editing and RNA therapies has put CRISPR Therapeutics (CRSP) in focus, even as the company ...

A research group led by Associate Professor Tetsuya Muramoto from the Faculty of Science, Toho University, has established a CRISPR genome editing technique that enables comparative analysis of the ...

CRISPR Therapeutics AG reported a Q1 net loss of $136m, but maintains a strong cash position with $1.86bn in cash and marketable securities. Casgevy, a gene therapy for Sickle Cell Disease, has seen ...

UC San Diego researchers have created a new system that reveals specific categories of potentially risky mutations resulting from CRISPR edits. This high magnification image reveals CRISPR-based DNA ...

Researchers at Vilnius University (Lithuania) have uncovered how the bacterial protein Cas9, better known as the CRISPR-Cas ...

CRISPR gene drives bias inheritance in pests, advancing population-level control while raising questions about resistance and ...

Using a CRISPR-based biosensor platform, researchers have detected microRNA biomarkers of Alzheimer’s disease, with the ...

Investigators at CHOP and UPenn found that lower cell counts could still be associated with poor outcomes if the cells were ...

Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...